GMP Human VEGF165 Protein

DMF
Premium grade (Pre-GMP) version VE5-H4210 is now available for seamless transition.
1/9
+6 View all
製品番号/仕様
価格
Availability
数量
GMP-VE5H23-50ug
$570.00
In Stock - Delivery in 2-3 business days
GMP-VE5H23-1mg (50ug X 20)
$4,325.00
In Stock - Delivery in 2-3 weeks
GMP-VE5H23-10mg (50ug X 200)
$30,275.00
GMP-VE5H23
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Product Details

VEGF165​ is the predominant isoform of Vascular Endothelial Growth Factor, belonging to the Platelet-Derived Growth Factor (PDGF) family. It serves as a key cytokine regulating angiogenesis and endothelial cell function. During the differentiation of human pluripotent stem cells (hPSCs) toward endothelial cells, VEGF165 drives mesoderm cells toward endothelial progenitors and promotes endothelial cell proliferation, migration, and tube formation. In protocols for differentiation into immune cells, VEGF165 supports the construction of a vascular-like microenvironment, indirectly facilitating the homing and differentiation of hematopoietic stem/progenitor cells. It plays a synergistic role, particularly in the differentiation of myeloid immune cells such as macrophages and dendritic cells, and is often combined with cytokines like SCF, FLT3L, and IL-3 to enhance differentiation efficiency and functional maturation.

Product Features and Advantages
  • Specific Angiogenic & Hematopoietic Driver​​: Efficiently supports hPSC-derived hematopoietic stem/progenitor cell (HSPC) expansion and endothelial cell differentiation.
  • Reliable Large-Scale Supply: Ensures batch production capacity, supporting robust and consistent manufacturing scale-up.
  • High Lot-to-Lot Consistency​: Ensures reliable and reproducible performance in every batch, supporting scalable applications.
GMP Platform Advantages
  • Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
  • End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
  • Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
  • Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
  • Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
  • Professional Support: Extensive manufacturing and application expertise to accelerate development.
Source

GMP Human VEGF165 Protein (GMP-VE5H23) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).

Predicted N-terminus: Ala 27

Molecular Characterization

This protein carries no "tag".

The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 10 EU/mg, tested by the LAL method in compliance with USP <85> and Ph. Eur. 2.6.14.

Host Cell Protein

<0.5 ng/µg of protein tested by ELISA.

Host Cell DNA

<0.02 ng/μg of protein tested by qPCR.

Sterility

Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

Mycoplasma

Negative

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with protectants.

Contact us for customized product form or formulation.

Vial Specification

2R (13 mm neck finish)

Shipping and Storage

This product is supplied and shipped on blue ice.

Upon receipt, store it immediately at -20°C or lower for long term storage.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 5 years in lyophilized state;
  • -70°C for 12 months under sterile conditions after reconstitution.

バックグランド

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.